ADMA Biologics Dividendos y recompras
Dividendo controles de criterios 0/6
ADMA Biologics no tiene historial de pago de dividendo.
Información clave
n/a
Rentabilidad por dividendo
1.6%
Rendimiento de la recompra
| Rendimiento total para el accionista | 1.6% |
| Rendimiento futuro de los dividendos | n/a |
| Crecimiento de los dividendos | n/a |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Ratio de pago | n/a |
Últimas actualizaciones de dividendos y recompras
No hay actualizaciones
Recent updates
ADMA: Long Term Guidance And Buybacks Will Counter Post Short Report Caution
Analysts have trimmed their view on ADMA Biologics, cutting the consensus price target by $6 to reflect increased caution following recent downgrades and questions raised after a short report, even as long term profitability assumptions and P/E expectations remain broadly steady. Analyst Commentary Recent research updates point to a more cautious tone around ADMA Biologics, with bearish analysts trimming price targets and shifting ratings to reflect higher perceived risk following the short report and subsequent uncertainty.ADMA: Long Term Guidance And Buybacks Will Support Post Short Report Upside
Analysts have nudged their price target for ADMA Biologics to $17.00, reflecting updated assumptions on revenue growth, profit margins, discount rate and future P/E following recent downgrades and reduced clarity cited in Street research. Analyst Commentary Recent Street research has taken a more cautious stance on ADMA Biologics, with bearish analysts reassessing their views after a short report introduced fresh uncertainty around the story.ADMA Biologics: Differentiated Plasma Approach With Asymmetric Upside Potential (Rating Upgrade)
Mar 29ADMA: Long Term Revenue Guidance And Buybacks Will Support Bullish Outlook
Analysts are maintaining their $17.00 price target on ADMA Biologics, as only minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions do not materially change their view of the stock's valuation. What's in the News ADMA completed a share repurchase program announced on May 7, 2025, buying back a total of 1,919,070 shares, or 0.8% of shares, for US$31.92 million, including 590,422 shares, or 0.25% of shares, for US$8.91 million between October 1, 2025 and December 31, 2025 (Key Developments).
ADMA: Multiyear Revenue Guidance And Share Buybacks Will Support Future Upside
Analysts have modestly revised their price target on ADMA Biologics to $30.00, reflecting updated assumptions around slightly lower revenue growth, a higher profit margin, and a somewhat lower future P/E multiple. The fair value estimate remains at $30.00.ADMA: Long-Term Revenue Outlook And Margins Will Support Current Fair Value
Analysts have modestly fine tuned their price target on ADMA Biologics to $17.00, citing slightly higher modeled revenue growth and profit margins, along with a marginally lower future P/E assumption, as key drivers of their updated view. What's in the News ADMA Biologics issued earnings guidance for 2027, expecting total revenue of approximately $775m.ADMA: Long Term Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value target for ADMA Biologics at $30.00. They have made small adjustments to inputs such as discount rate, revenue growth, profit margin, and future P/E to fine-tune their underlying assumptions rather than alter the headline valuation.ADMA: Raised Revenue Guidance And Margin Gains Will Offset Higher Discount Rate
Analysts have raised their price target on ADMA Biologics to US$17.00, reflecting updated views on slightly higher projected revenue growth, a stronger profit margin profile, a modest adjustment to the discount rate, and a lower assumed future P/E multiple. What's in the News Raised preliminary unaudited earnings guidance for fiscal 2025, with total revenue now expected between approximately US$510 million and US$511 million (Corporate Guidance: Raised).ADMA: Raised Long Term Revenue Guidance And Buybacks Will Support Upside
Analysts have trimmed their price target on ADMA Biologics from US$35.00 to US$30.00, pointing to updated assumptions around a modestly higher discount rate, slightly lower revenue growth expectations, a higher projected profit margin, and a lower future P/E multiple. What's in the News ADMA Biologics completed a share repurchase program announced on May 7, 2025, buying back a total of 1,328,648 shares, or 0.56% of shares, for US$23.01 million, including 512,411 shares, or 0.21%, for US$8.03 million from July 1 to September 30, 2025 (Key Developments).ADMA: Higher Discount Rate Will Outweigh Stronger Revenue Outlook
Analysts have trimmed their price target on ADMA Biologics from 19.24 dollars to 17.00 dollars, citing the need for a slightly higher discount rate and modestly lower long term margin assumptions, despite a somewhat stronger revenue growth outlook and more conservative future valuation multiples. What's in the News Raised revenue guidance for fiscal 2025 to at least $510 million, up from more than $500 million previously (Company guidance) Increased fiscal 2026 revenue outlook to at least $630 million, compared with prior guidance of $625 million or more (Company guidance) Introduced long term guidance targeting total annual revenue of $1.1 billion or more by 2029, with expectations for earnings growth above current margin levels (Company guidance) Completed a share repurchase of 1,328,648 shares, or 0.56 percent of outstanding shares, for $23.01 million under the buyback program announced on May 7, 2025, including 512,411 shares repurchased in the most recent tranche (Buyback update) Valuation Changes Fair Value Estimate trimmed from $19.24 to $17.00, a modest downward revision of roughly 12 percent.
ADMA: Share Repurchases And Long Term Revenue Outlook Will Drive Future Upside
Narrative Update on ADMA Biologics Analysts have maintained their price target for ADMA Biologics at 27.25 dollars, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margins, and future valuation multiples. This signals continued confidence in the company’s long term earnings trajectory and risk profile.ADMA Biologics, Inc. (NASDAQ:ADMA) Looks Just Right With A 25% Price Jump
Dec 02
ADMA: Share Repurchases And Rising Earnings Guidance Will Support Future Upside
Analysts have maintained their price target for ADMA Biologics at $27.25 per share, citing stable financial projections and consistent optimism regarding the company's growth prospects. What's in the News From July 1, 2025 to September 30, 2025, ADMA Biologics repurchased 512,411 shares, completing a total buyback of 1,328,648 shares for $23.01 million as announced in May 2025 (Key Developments).ADMA: Buyback Activity And Margin Expansion Will Drive Robust Results
Analysts have increased their price target for ADMA Biologics to $27.25. They cite expectations for stronger revenue growth and higher profit margins, balanced against a slightly higher discount rate and declining future price-to-earnings multiples.Share Repurchase And Higher Margins Will Drive Future Upside Potential
Analysts have slightly lowered their price target for ADMA Biologics from $27.81 to $27.25. They cited modest adjustments in financial assumptions, including revenue growth and profit margins.Optimized Yield Process And Expanding Capacity Will Build Lasting Momentum
Analysts have lowered their price target for ADMA Biologics from $29.06 to $27.81, primarily because of slight adjustments in fair value and future price-to-earnings estimates. Revenue growth and profit margin projections remain largely unchanged.ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential
Mar 21Revenues Not Telling The Story For ADMA Biologics, Inc. (NASDAQ:ADMA)
Feb 26ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add
Feb 06Does ADMA Biologics (NASDAQ:ADMA) Have A Healthy Balance Sheet?
Dec 31ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
Dec 02Subdued Growth No Barrier To ADMA Biologics, Inc. (NASDAQ:ADMA) With Shares Advancing 36%
Nov 26Valuation analysis
11-NOV-2024Actual company guidance: 2024: 415 MUSD revenue (S24) and net income 120 MUSD (E24), 2025: 465 MUSD (S25), 165 MUSD net income (E25)Market cap of 5.35 BUSD (P) at 22.62/share: P/S24 = 12.9,ADMA Biologics, Inc.'s (NASDAQ:ADMA) 27% Price Boost Is Out Of Tune With Revenues
Oct 09ADMA Biologics: Riding High On ASCENIV's Success
Oct 02ADMA Biologics, Inc.'s (NASDAQ:ADMA) Intrinsic Value Is Potentially 57% Above Its Share Price
Sep 06
ASCENIV Drives Revenue Surge, Shaping A Bright Future For The Biotech Leader
ADMA Biologics showcases rapid revenue growth and operational efficiency, with ASCENIV's success significantly impacting future growth.ADMA Biologics' (NASDAQ:ADMA) Strong Earnings Are Of Good Quality
Aug 16ADMA Biologics: A Compelling GARP Stock For Biotech Investors
Jul 27ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 24Is ADMA Biologics (NASDAQ:ADMA) Using Too Much Debt?
Jul 17Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ADMA han sido estables en el pasado.
Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ADMA han aumentado.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de ADMA Biologics vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (ADMA) | n/a |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.2% |
| Media de la industria (Biotechs) | 2.5% |
| Analista de previsiones (ADMA) (hasta 3 años) | n/a |
Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ADMA en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ADMA en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.
Pago de beneficios a los accionistas
Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de ADMA para determinar si sus pagos de dividendos están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ADMA no ha comunicado ningún pago.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/01 12:31 |
| Precio de las acciones al final del día | 2026/04/30 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
ADMA Biologics, Inc. está cubierta por 11 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gary Nachman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Prem Chulaki | CrispIdea |